BackActuate Therapeutics Overview

Actuate Therapeutics Accounts Payable

Track Actuate Therapeutics's accounts payable ($1.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$1.20M
↓ 54.57% YoYΔ $-1.44M vs prior year quarter

Peer average

Loading

Actuate Therapeutics Accounts Payable History

Loading

Actuate Therapeutics vs. peers: Accounts Payable Comparison

Loading

Actuate Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Actuate Therapeutics (ACTU) FAQ

As of the most recent data (March 2026), ACTU shows a accounts payable of $1.2M. That compares with $2.6M in the prior-year period — down 54.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ACTU's accounts payable is now $1.2M (was $2.6M) — a 54.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Actuate Therapeutics is outperforming or lagging.

Tracking ACTU's accounts payable over time shows whether Actuate Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2M That compares with $2.6M in the prior-year period — down 54.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Actuate Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1.2M) with ownership activity and broader fundamentals.